Seres stockholders approve increase in authorized shares from 200M to 240M at annual meeting

Seres Therapeutics, Inc.

All three Class II director nominees elected: Berenson, Kender, and Fraser.
Amendment to increase authorized common shares to 240M approved with 98.4% of votes cast in favor.
Ratification of PwC as auditor for FY2023 approved with 99.8% of votes cast in favor.
Advisory vote on executive compensation passed with approximately 99.4% of votes cast in favor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.